FULVESTRANT

all catalysts(4)

News(10)

• AstraZeneca’s newly approved pill fails frontline breast cancer study
  Etcamah is the second oral “SERD” to recently fall short in first-line breast cancer, following a similar setback from Roche earlier this year.
  biopharma_dive · 16d ago
• Celcuity gains FDA approval for closely watched breast cancer drug
  Still, shares fell by nearly 20% after the company revealed a delay in the coming launch of Revtorpyk. Details in the drug’s prescribing information surprised some analysts, too.
  biopharma_dive · 2mo ago
• Celcuity wins approval for breast cancer drug Revtorpyk
  A small public biotech won approval for a breast cancer drug that was designed to improve on similar treatments from Novartis and Roche. The FDA on Tuesday cleared Celcuity's Revtorpyk in combinati…
  endpoints · 2mo ago
• Evolving Oral SERD Research Seeks to Redefine Treatment Strategies in Hormone Receptor+ Breast Cancer
  Breast cancer experts discuss the nuances of ESR1 mutations and oral SERD use in hormone receptor–positive breast cancer.
  onclive · 4mo ago
• Dr McCann on the FDA Approval of Vepdegestrant for ESR1-Mutated, ER+ Advanced Breast Cancer
  Kelly Elizabeth McCann, MD, PhD, notes the role of vepdegestrant in the ESR1-mutated, ER-positive, HER2-negative advanced breast cancer treatment paradigm.
  onclive · 4mo ago
• Honesty and Humor Provide Hope in Breast Cancer Survivorship: With Sara Nunnery, MD, MSCI; and Annie Bond
  Dr Nunnery and Annie Bond discuss breast cancer survivorship and patient advocacy.
  onclive · 4mo ago
• Dr Silbermann on Clinical Trial Design Considerations in Multiple Myeloma
  Rebecca Silbermann, MD, MMS, outlines key trial design considerations in multiple myeloma, including supportive care measures and end point selection.
  onclive · 4mo ago
• MimiVax and Roswell Park Open Phase 2 Trial of SurVaxM for Patients with Metastatic Neuroendocrine Tumors
  Roswell Park Comprehensive Cancer Center launched a phase 2 trial evaluating SurVaxM plus temozolomide in progressing neuroendocrine tumors.
  onclive · 4mo ago
• Dr Randall on the Rationale for Investigating CSF-1R Inhibition in TGCT
  R. Lor Randall, MD, FACS discusses safety and efficacy data from the MANEUVER trial, which evaluated pimicotinib in TGCT.
  onclive · 4mo ago
• RAPNO Criteria and MRI Assessment in PLGG: Recommendations vs. Real-World Practice
  Learn how clinicians weigh symptoms, MRI changes and family goals to decide when a child’s tumor needs treatment—beyond simple size cutoffs.
  onclive · 4mo ago